MorphoSys has appointed four leading experts to its newly formed Scientific Advisory Board (SAB). The SAB is set up to consult the Company with regard to strategic options and future perspectives within its research and development activities. The goal of the SAB is thus to further strengthen MorphoSys's leadership position in discovery and clinical development of antibody and peptide-based therapies for cancer, inflammation and other therapeutic fields of high medical need.

The inaugural members of MorphoSys's Scientific Advisory Board are:

  • Dr. Günther R. Adolf (former Vice President Pharmacology and Deputy Head of Oncology Research at Boehringer Ingelheim, Vienna, Austria),
  • Prof. Dr. Bruce D. Cheson (Professor of Medicine & Deputy Chief, Division of Hematology and Oncology, Georgetown University Hospital, Washington D.C., USA),
  • Dr. Sergio Quezada (Professorial Research Fellow and Group Leader, Immune Regulation and Tumor Immunotherapy, University College London Cancer Institute, London, UK), and
  • Dr. Raymond W. Sweet (pictured – former Senior Director and Fellow, Biologics Research at Janssen, J&J, Pennsylvania, USA).